Leung Kevin Matthew Yen Bing, Alrabeeah Khalid, Carrier Serge
McGill University, 9D-1210 Boulevard de Maisonneuve Ouest, Montreal, QC, H3A0A2, Canada,
Curr Urol Rep. 2015 Aug;16(8):57. doi: 10.1007/s11934-015-0523-9.
Late-onset male hypogonadism has long been recognized as a treatable medical condition; however, misconceptions about the use of testosterone replacement therapy (TRT) have often led urologists away from its more mainstream use. This paper aims to bring the reader up-to-date on the current understanding of TRT, starting with when and who to treat. Various formulations of TRT, each with its own risks and benefits, are also detailed. Finally, a comprehensive analysis of the current literature's views into the various controversies of TRT including its impact on prostate health, sexual health, cardiovascular health, frailty, and mood is discussed.
迟发性男性性腺功能减退长期以来一直被认为是一种可治疗的病症;然而,关于睾酮替代疗法(TRT)使用的误解常常使泌尿科医生不采用这种更为主流的治疗方法。本文旨在使读者了解TRT的当前认识,首先介绍何时治疗以及治疗对象。还详细阐述了TRT的各种制剂,每种制剂都有其自身的风险和益处。最后,讨论了对当前文献中关于TRT各种争议观点的全面分析,包括其对前列腺健康、性健康、心血管健康、虚弱和情绪的影响。